Structured population data were available for 4 of 4 supporting studies. 2 studies described participants with type 2 diabetes. 4 studies described adult participants.

1 relevant study has unresolved authoritative design evidence and does not contribute to design-specific or RoB-specific claims.

2 supporting studies do not have a displayable topic-matched quantitative effect.

Evidence uses heterogeneous comparison contexts: active_comparator, placebo, unknown_unresolved.

1 supporting study has high, serious, critical, unclear, or unavailable risk-of-bias information.

2 of 4 studies with duration data have follow-up of 12 weeks or less.

Placebo

Core clinician-reference fields are available or not applicable.

Participants received metformin for 3 months followed by a washout period and then switched to placebo for another 3 months.

Metformin

Participants were randomly assigned in a 1:1 ratio to receive either metformin or placebo for 3 months. Then, after a 1-month washout period (116 half-lives for metformin), the medication was changed to the other treatment for another 3 months.

Participants received placebo for 3 months followed by a washout period and then switched to metformin for another 3 months.

Metformin improves glycemic control in heart failure patients

Not extracted from the authoritative source.

Available source content was suppressed because validation identified a conflict.

Clinician-reference record is usable with limitations in: comparator.

Control group receiving metformin tablets daily for 45 days.

Group A (Control)

In Group A (Control), metformin tablets (500 mg) will be prescribed daily once before lunch with plain water for 45 consecutive days.

Interventional group receiving Nimba-Amalakyadi formulation twice daily for 45 days.

Group B (Interventional group)

In Group B (Interventional group), the Nimba-Amalakyadi formulation will be prescribed 5 grams twice daily with an empty stomach (ie, 7 AM-5 PM) with lukewarm water for 45 consecutive days.

Authoritative quality diagnostic: invalid or missing value.

Nimba Amalakyadi Improves Glycemic Control in Type 2 Diabetes

Postmeal Metformin Group

Participants received metformin before meals for 4 weeks.

Premeal Metformin Group

All participants were randomly assigned to receive immediate-release metformin either 30–60 min before or immediately after meal for 4 weeks.

Participants received metformin after meals for 4 weeks.

Premeal metformin improves postmeal glucose control in diabetes.

Source evidence could not be resolved sufficiently for this field.

Clinician-reference record is usable with limitations in: design, comparator, risk_of_bias.

Patients receiving metformin as monotherapy.

Metformin group (Group M)

Patients receiving metformin 1000 mg once daily were taken in Group M.

Patients receiving metformin plus ranolazine.

Metformin plus ranolazine group (Group M+R)

Patients receiving metformin 1000 mg once daily plus ranolazine were enrolled in Group M+R.

Authoritative quality diagnostic: source evidence unresolved.

Metformin × Glucose iAUC (OGTT)

Available supporting studies

Metformin improves glycemic control in heart failure patients

Nimba Amalakyadi Improves Glycemic Control in Type 2 Diabetes

Premeal metformin improves postmeal glucose control in diabetes.

Ranolazine improves glycaemic control when added to metformin in T2DM patients